![](https://investorshub.advfn.com/uicon/158678.png?cb=1661594561)
Friday, November 19, 2021 7:16:54 AM
"The adverse effect of Heparin was not known at the time the trial was designed."
Are you sure of that?
Besides, last I heard the amount of heparin used wouldn't have had a significant effect.
My "last I heard" was based on two sources.....The CEO's statement, which you consider to be not definitive, and a statistical analysis done by farrell90 which can be found at https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166670757 . The latter seemed thorough...not sure if you would consider it definitive.
"The adverse effect of Heparin was not known at the time the trial was designed."
"Given heparin is dosed at such low concentrations, we wouldnt anticipate any large effect of Heparin on Brilacidin's blocking property in the COVID trial."
Did the CEO reach that conclusion before the trial design was finalized or did he not know that it needed to be considered?
It's hard to see it both ways. If he didn't know of the possibility of an adverse effect of Heparin before the trial was designed he should have, shouldn't he? Or he did know, considered it to be negligible, and you're mistaken in your statement. Pick one.
Furthermore we'd have to believe that no one saw fit to do the farrell90 analysis prior to the design of the trial if your statement about the adverse effect of Heparin not being known before the trial was designed to be accepted.
Please consider the above.
I expect you found the paper reference less compelling given that you left it unaddressed.
I believe the heparin issue was known to Scott and Degrado in 2014 based on my amateurish interpretation of the paper that they authored (with others). You didn't address that possibility and I can't blame you for that....I didn't offer it as definitive proof, but it seemed to me to be at least suggestive of SOME KNOWLEDGE of the issue by CTIX closely related parties.
"De novo design of self-assembling foldamers that inhibit heparin-protein interactions"
https://pubmed.ncbi.nlm.nih.gov/24491145/
Bottom line?
The "heparin effect" would only matter to the extent that it affected the trial results and the CEO and farrell90 both seem to think that it couldn't have. I hope they're right.
As my dear old grandfather Litvak said (just before they swung the trap), he said "You can't cheat an honest man. Never give a sucker an even break or smarten up a chump."
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM